Industry experts say a receptive market and investor interest in new technologies have spurred the increase in genomics tools and molecular diagnostics IPOs.
Ascend Clinical Laboratory said it replaced its existing Siemens analyzers with the Atellica to manage growth, including during periods of high demand.
Roche Diagnostics got the nod for its Elecsys Anti-HAV II test for the detection of total antibodies — IgG and IgM — to the hepatitis A virus.
The firm anticipates that point-of-care adoption may attract licensing deals from companies interested in adding the biomarkers to their large laboratory analyzers.
Siemens Healthineers received clearances for an assay used to detect and monitor acute pancreatitis, and for tests and controls used to detect Zika.
With the firm seeing lower profitability in diagnostics, its CEO said it is focusing on improving earnings strength with the Atellica Solution IVD platform.
According to the company, it has shipped more than 1,700 of the IVD analyzer platforms since launching sales globally in 2017.
Siemens Healthineers received clearance for its Dimension Exl High-Sensitivity Troponin I Assay used to diagnose acute myocardial infarction.
A Roche executive said he expects essentially all the firm's US troponin customers will convert to the high-sensitivity assay over the next two to three years.